• 1
    Rosenberg SA,Yang JC,Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10: 90915.
  • 2
    Ohnmacht GA,Wang E,Mocellin S,Abati A,Filie A,Fetsch P,Riker AI,Kammula US,Rosenberg SA,Marincola FM. Short-term kinetics of tumor antigen expression in response to vaccination. J Immunol 2001; 167: 180920.
  • 3
    Marincola FM,Jaffee EM,Hicklin DJ,Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000; 74: 181273.
  • 4
    Jager E,Ringhoffer M,Altmannsberger M,Arand M,Karbach J,Jager D,Oesch F,Knuth A. Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int J Cancer 1997; 71: 1427.
  • 5
    Natali PG,Imai K,Wilson BS,Bigotti A,Cavaliere R,Pellegrino MA,Ferrone S. Structural properties and tissue distribution of the antigen recognized by the monoclonal antibody 653.40S to human melanoma cells. J Natl Cancer Inst 1981; 67: 591601.
  • 6
    Campoli MR,Chang CC,Kageshita T,Wang X,McCarthy JB,Ferrone S. Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance. Crit Rev Immunol 2004; 24: 26796.
  • 7
    Luo W,Ko E,Hsu JC,Wang X,Ferrone S. Targeting melanoma cells with human high molecular weight-melanoma associated antigen-specific antibodies elicited by a peptide mimotope: functional effects. J Immunol 2006; 176: 604654.
  • 8
    Ross AH,Cossu G,Herlyn M,Bell JR,Steplewski Z,Koprowski H. Isolation and chemical characterization of a melanoma-associated proteoglycan antigen. Arch Biochem Biophys 1983; 225: 37083.
  • 9
    Iida J,Meijne AM,Spiro RC,Roos E,Furcht LT,McCarthy JB. Spreading and focal contact formation of human melanoma cells in response to the stimulation of both melanoma-associated proteoglycan (NG2) and α 4 β 1 integrin. Cancer Res 1995; 55: 217785.
  • 10
    de Vries JE,Keizer GD,Te Velde AA,Voordouw A,Ruiter D,Rumke P,Spits H,Figdor CG. Characterization of melanoma-associated surface antigens involved in the adhesion and motility of human melanoma cells. Int J Cancer 1986; 38: 46573.
  • 11
    Harper JR,Reisfeld RA. Inhibition of anchorage-independent growth of human melanoma cells by a monoclonal antibody to a chondroitin sulfate proteoglycan. J Natl Cancer Inst 1983; 71: 25963.
  • 12
    Iida J,Pei D,Kang T,Simpson MA,Herlyn M,Furcht LT,McCarthy JB. Melanoma chondroitin sulfate proteoglycan regulates matrix metalloproteinase-dependent human melanoma invasion into type I collagen. J Biol Chem 2001; 276: 1878694.
  • 13
    Ozerdem U,Stallcup WB. Pathological angiogenesis is reduced by targeting pericytes via the NG2 proteoglycan. Angiogenesis 2004; 7: 26976.
  • 14
    Chekenya M,Hjelstuen M,Enger PO,Thorsen F,Jacob AL,Probst B,Haraldseth O,Pilkington G,Butt A,Levine JM,Bjerkvig R. NG2 proteoglycan promotes angiogenesis-dependent tumor growth in CNS by sequestering angiostatin. FASEB J 2002; 16: 5868.
  • 15
    Ozerdem U. Targeting pericytes diminishes neovascularization in orthotopic uveal melanoma in nerve/glial antigen 2 proteoglycan knockout mouse. Ophthalmic Res 2006; 38: 2514.
  • 16
    Ozerdem U. Targeting of pericytes diminishes neovascularization and lymphangiogenesis in prostate cancer. Prostate 2006; 66: 294304.
  • 17
    Rammensee H,Bachmann J,Emmerich NP,Bachor OA,Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999; 50: 2139.
  • 18
    Ho A,Schwarze SR,Mermelstein SJ,Waksman G,Dowdy SF. Synthetic protein transduction domains: enhanced transduction potential in vitro and in vivo. Cancer Res 2001; 61: 4747.
  • 19
    Thurner B,Roder C,Dieckmann D,Heuer M,Kruse M,Glaser A,Keikavoussi P,Kampgen E,Bender A,Schuler G. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Methods 1999; 223: 115.
  • 20
    Jonuleit H,Kuhn U,Muller G,Steinbrink K,Paragnik L,Schmitt E,Knop J,Enk AH. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 1997; 27: 313542.
  • 21
    Consogno G,Manici S,Facchinetti V,Bachi A,Hammer J,Conti-Fine BM,Rugarli C,Traversari C,Protti MP. Identification of immunodominant regions among promiscuous HLA-DR restricted CD4+ T cell epitopes on the tumor antigen MAGE-3. Blood 2003; 101: 13844.
  • 22
    Schrappe M,Bumol TF,Apelgren LD,Briggs SL,Koppel GA,Markowitz DD,Mueller BM,Reisfeld RA. Long-term growth suppression of human glioma xenografts by chemoimmunoconjugates of 4-desacetylvinblastine-3-carboxyhydrazide and monoclonal antibody 9.2.27. Cancer Res 1992; 52: 383844.
  • 23
    Chang CC,Campoli M,Luo W,Zhao W,Zaenker KS,Ferrone S. Immunotherapy of melanoma targeting human high molecular weight melanoma-associated antigen: potential role of non-immunological mechanisms. Ann NY Acad Sci 2004; 1028: 34050.
  • 24
    Godal A,Kumle B,Pihl A,Juell S,Fodstad O. Immunotoxins directed against the high-molecular-weight melanoma-associated antigen. Identification of potent antibody-toxin combinations. Int J Cancer 1992; 52: 6315.
  • 25
    Spitler LE,Mischak R,Scannon P. Therapy of metastatic malignant melanoma using Xomazyme Mel, a murine monoclonal anti-melanoma ricin A chain immunotoxin. Int J Rad Appl Instrum B 1989; 16: 6257.
  • 26
    Schroff RW,Foon KA,Beatty SM,Oldham RK,Morgan AC,Jr. Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res 1985; 45: 87985.
  • 27
    Bumol TF,Wang QC,Reisfeld RA,Kaplan NO. Monoclonal antibody and an antibody-toxin conjugate to a cell surface proteoglycan of melanoma cells suppress in vivo tumor growth. Proc Natl Acad Sci USA 1983; 80: 52933.
  • 28
    Mittelman A,Chen ZJ,Yang H,Wong GY,Ferrone S. Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. Proc Natl Acad Sci USA 1992; 89: 46670.
  • 29
    Erfurt C,Sun Z,Haendle I,Schuler-Thurner B,Heirman C,Thielemans K,van der Bruggen P,Schuler G,Schultz ES. Tumor-reactive CD4+ T cell responses to the melanoma-associated chondroitin sulphate proteoglycan in melanoma patients and healthy individuals in the absence of autoimmunity. J Immunol 2007; 178: 77039.
  • 30
    Oldham RK,Foon KA,Morgan AC,Woodhouse CS,Schroff RW,Abrams PG,Fer M,Schoenberger CS,Farrell M,Kimball E. Monoclonal antibody therapy of malignant melanoma: in vivo localization in cutaneous metastasis after intravenous administration. J Clin Oncol 1984; 2: 123544.
  • 31
    Buraggi GL,Callegaro L,Mariani G,Turrin A,Cascinelli N,Attili A,Bombardieri E,Terno G,Plassio G,Dovis M. Imaging with 131I-labeled monoclonal antibodies to a high-molecular-weight melanoma-associated antigen in patients with melanoma: efficacy of whole immunoglobulin and its F(ab′)2 fragments. Cancer Res 1985; 45: 337887.
  • 32
    Siccardi AG,Buraggi GL,Callegaro L,Mariani G,Natali PG,Abbati A,Bestagno M,Caputo V,Mansi L,Masi R. Multicenter study of immunoscintigraphy with radiolabeled monoclonal antibodies in patients with melanoma. Cancer Res 1986; 46: 481722.
  • 33
    Hurwitz H,Fehrenbacher L,Novotny W,Cartwright T,Hainsworth J,Heim W,Berlin J,Baron A,Griffing S,Holmgren E,Ferrara N,Fyfe G, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 233542.
  • 34
    Forstpointner R,Dreyling M,Repp R,Hermann S,Hanel A,Metzner B,Pott C,Hartmann F,Rothmann F,Rohrberg R,Bock HP,Wandt H, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004; 104: 306471.
  • 35
    Slamon DJ,Leyland-Jones B,Shak S,Fuchs H,Paton V,Bajamonde A,Fleming T,Eiermann W,Wolter J,Pegram M,Baselga J,Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over expresses HER2. N Engl J Med 2001; 344: 78392.